HTB

Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study

Simon Collins, HIV i-Base

The BLAZE-2 study randomised 1175 residents or staff who were at high risk of COVID-19 through living or working in residential care homes to either bamlanivimab or placebo.

Of these, 966/1175 were PCR negative, using bamlanivimab as prophylaxis and 209/1175 were PCR positive, using the intervention as treatment.

Participants in the prevention group needed to be PCR negative at baseline with a primary endpoint of incidence of COVID-19 symptoms and secondary endpoint of PCR-positive transmission, both at day 57.

Full results presented at CROI 2021 showed an 80% reduced risk of symptoms: OR 0.20 (95%CI: 0.08 to 0.49), p<0.001.

The top line results from this study had been released in a company press statement in January. [2]

References

  1. Cohen M et al. Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting. CROI 2021, virtual. Oral abstract 121.
    https://ww2.aievolution.com/cro2101/index.cfm?do=abs.viewAbs&abs=2538 (abstract)
    https://www.vcroi2021.org/live-stream/19762744/NEW-WEAPONS-AGAINST-SARS-CoV-2-AND-HIV (webcast)
  2. Bamlanivimab (LY-CoV555) prophylaxis prevents COVID-19 in care homes: results of BLAZE-2 study. HTB (24 February 2021).
    https://i-base.info/htb/39886

This report was first published on 19 March 2021.

Links to other websites are current at date of posting but not maintained.